At 4.2% CAGR, South & Central America Feed Anticoccidials Market is Projected to be Worth US$ 245.71 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the South & Central America feed anticoccidials market was valued at US$ 176.63 million in 2023 and is expected to reach US$ 245.71 million by 2031, registering a CAGR of 4.2% from 2023 to 2031. Adoption of bio shuttle program for managing coccidiosis and rise in prevalence of coccidiosis are among the critical factors attributed to the South & Central America feed anticoccidials market expansion.

The bio shuttle program involves strategically using advanced technologies and practices to prevent coccidiosis and enhance bird health and performance. Two main ingredients in a bio shuttle program-vaccines and anticoccidials-are combined to improve poultry health and are essential to the program's continued effectiveness. Birds receive a coccidiosis vaccine at the hatchery; then, an in-feed anticoccidial is administered. Vaccines are all comprised of live Eimeria, which stimulate immunity by providing controlled exposure to coccidia and coccidial cycling. Eimeria, most often associated with Necrotic enteritis (NE), develops deep in the gastrointestinal issue. Thus, in-feed anticoccidials are used in the bio shuttle program after vaccination to lower the peak cycling of the Eimeria.

Producers can improve the general health of their flock by offering complete protection against parasite risks by combining vaccinations with anticoccidials through the bio shuttle program. The program that incorporates in-feed anticoccidials fights against coccidiosis throughout the production cycle and reduces the risk of disease outbreaks. A bio shuttle program can improve feed conversions and weight gain while assisting in managing intestinal injury. Thus, the rising adoption of bio shuttle programs is expected to become a significant trend in the feed anticoccidials market during the forecast period.

On the contrary, stringent regulation on use of antibiotics in animal feed hamper the growth of South & Central America feed anticoccidials market.

Based on type, the South & Central America feed anticoccidials market is segmented into ionophore, chemical anticoccidials, and chemical-ionophores. The ionophore segment held 46.7% market share in 2023, amassing US$ 82.57 million. It is projected to garner US$ 111.74 million by 2031 to register 3.9% CAGR during 2023-2031.

In terms of form, the South & Central America feed anticoccidials market is bifurcated into dry and liquid. The dry segment held 95.8% share of South & Central America feed anticoccidials market in 2023, amassing US$ 169.22 million. It is projected to garner US$ 234.85 million by 2031 to expand at 4.2% CAGR during 2023-2031.

Based on livestock, the South & Central America feed anticoccidials market is segmented into poultry, ruminants, swine, and others. The poultry segment held 81.6% market share in 2023, amassing US$ 144.07 million. It is projected to garner US$ 199.05 million by 2031 to register 4.1% CAGR during 2023-2031.

Based on country, the South & Central America feed anticoccidials market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 51.4% share of South & Central America feed anticoccidials market in 2023. It was assessed at US$ 90.77 million in 2023 and is likely to hit US$ 126.91 million by 2031, exhibiting a CAGR of 4.3% during 2023-2031.

Key players operating in the South & Central America feed anticoccidials market are Phibro Animal Health Corp, Zoetis Inc, Kemin Industries Inc, Elanco Animal Health Inc, Huvepharma EOOD, Impextraco NV, and Virbac SA., among others.

• In April 2024, Zoetis and Phibro Animal Health acquired Zoetis' medicated feed additive product portfolio, water soluble products, and related assets for $350 million. The acquisition, which generated $400 million in revenue in 2023, includes over 37 product lines and six manufacturing sites. The transaction is expected to be completed in the second half of 2024. Over 300 Zoetis colleagues are expected to transition to Phibro Animal Health.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com